World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
39203
World Ranking
11585
National Ranking
622

Tanja Fehm publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Tanja Fehm sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,534 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Tanja Fehm D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Tanja Fehm sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2020 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Gynaecology and Paediatrics

Overview

Tanja Fehm is affiliated with Heinrich Heine University Düsseldorf in Germany. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in subfields including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology, and Obstetrics and Gynecology.

The scientist's research topics focus extensively on cancer and related therapeutic approaches. Key areas of study include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer Cells and Metastasis
  • Cancer Treatment and Pharmacology
  • Endometrial and Cervical Cancer Treatments

Among recent publications associated with this researcher are:

  • "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial" (2023, The Lancet)
  • "Recent advances in radiotherapy of breast cancer" (2020, Radiation Oncology)
  • "Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial" (2023, The Lancet)
  • "Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial" (2020, The Lancet Oncology)
  • "AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021" (2021, Breast Care)

The researcher frequently collaborates with a number of co-authors, including:

  • Peter A. Fasching (120 co-authored works)
  • Volkmar Müller (116 co-authored works)
  • Wolfgang Janni (114 co-authored works)
  • Andreas Schneeweiß (111 co-authored works)
  • Diana Lüftner (82 co-authored works)

Publications are often found in well-established venues such as:

  • Geburtshilfe und Frauenheilkunde (96 publications)
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie (52 publications)
  • Der Gynäkologe (20 publications)
  • Breast Care (18 publications)
  • Cancer Research (17 publications)

Tanja Fehm's work includes contributions relevant to both clinical oncology and molecular research. Their involvement with clinical trials and evidence-based treatment guidelines reflects an emphasis on translational medicine in oncology, particularly in breast cancer and gynecological malignancies.

In 2020, this scientist was recognized by election to the German National Academy of Sciences Leopoldina in the fields of Gynaecology and Paediatrics.

Best Publications

  • A pooled analysis of bone marrow micrometastasis in breast cancer

    Stephan Braun;Florian D. Vogl;Bjørn Naume;Wolfgang Janni

  • Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

    Thorsten Kuehn;Ingo Bauerfeind;Tanja Fehm;Barbara Fleige

  • Systemic spread is an early step in breast cancer.

    Yves Hüsemann;Jochen B. Geigl;Falk Schubert;Piero Musiani

  • Circulating tumor cells in patients with breast cancer dormancy

    Songdong Meng;Debasish Tripathy;Eugene P. Frenkel;Sanjay Shete

  • Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

    Bahriye Aktas;Mitra Tewes;Tanja Fehm;Siegfried Hauch

  • Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

    François-Clément Bidard;François-Clément Bidard;Dieter Peeters;Tanja Fehm;Franco Nolé

  • Early dissemination seeds metastasis in breast cancer

    Hedayatollah Hosseini;Milan M. S. Obradović;Martin Hoffmann;Kathryn L. Harper

  • Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

    Brigitte Rack;Christian Schindlbeck;Julia Jückstock;Ulrich Andergassen

  • HER-2 gene amplification can be acquired as breast cancer progresses.

    Songdong Meng;Debasish Tripathy;Sanjay Shete;Raheela Ashfaq

  • Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

    Gunter von Minckwitz;Holger Eidtmann;Mahdi Rezai;Peter A. Fasching

  • Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

    Sabine Riethdorf;Volkmar Müller;Liling Zhang;Thomas Rau

  • HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

    Tanja Fehm;Volkmar Müller;Bahriye Aktas;Wolfgang Janni

  • Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

    Sabine Kasimir-Bauer;Oliver Hoffmann;Diethelm Wallwiener;Rainer Kimmig

  • Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study

    Bernd Gerber;Gunter von Minckwitz;Heinrich Stehle;Toralf Reimer

  • Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

    Wolfgang J. Janni;Brigitte Rack;Leon W.M.M. Terstappen;Jean Yves Pierga

  • Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

    Frédéric Amant;Gunter von Minckwitz;Sileny N. Han;Marijke Bontenbal

  • Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.

    Christina S. Schuetz;Michael Bonin;Susan E. Clare;Kay Nieselt

  • Treatment of breast cancer during pregnancy: an observational study

    Sibylle Loibl;Sileny N Han;Gunter von Minckwitz;Marijke Bontenbal

  • MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.

    I. Keklikoglou;C. Koerner;C. Schmidt;J. D. Zhang

  • Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis

    Wolfgang Janni;Florian D. Vogl;Gro Wiedswang;Marit Synnestvedt

Frequent Co-Authors

Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Diethelm Wallwiener
Diethelm Wallwiener University of Tübingen
Volkmar Müller
Volkmar Müller Universität Hamburg
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Dieter Niederacher
Dieter Niederacher Heinrich Heine University Düsseldorf
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Klaus Pantel
Klaus Pantel Universität Hamburg
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Jens Huober
Jens Huober Kantonsspital St. Gallen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in Medicine doesn't always mean becoming a doctor. Many online degree options pave the way for rewarding roles in healthcare. For those interested in healthcare management, CAHME accredited online healthcare administration programs can help launch a career in hospital administration or healthcare leadership, all via flexible online study.

If you’re a registered nurse aiming to advance your credentials, some online RN to BSN programs no clinicals offer a pathway to complete your bachelor’s degree without additional hands-on clinical requirements. This makes career progression more accessible, even with a busy work schedule.

For those seeking the highest levels of practice and leadership, doctorate-level nursing programs are also available online. You can accelerate your education with short DNP programs or find options that balance rigor and flexibility among the easiest DNP programs. These routes are ideal for advancing in clinical practice, administration, or educational roles.

Whether you want to move into administration, improve patient outcomes, or lead teams, these online degrees offer multiple paths to achieve your healthcare career goals while maintaining flexibility.

Best Scientists Citing Tanja Fehm

Trending Scientists

Recently Published Articles